Zixuan Wang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Zixuan Wang has a total of 53 co-authors. Here are the top co-authors by number of shared publications:
- Ian Chi Kei Wong
The University of Hong Kong
6 shared publications - Kenneth Keng Cheung Man
The University of Hong Kong
5 shared publications - Ruth Brauer
University College London
4 shared publications - Angel Yun Sum Wong
Faculty of Epidemiology and Population Health London School of Hygiene and Tropical Medicine London UK
2 shared publications - Basmah H. Alfageh
King Saud University
2 shared publications - Celine Sze Ling Chui
School of Nursing, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, China
2 shared publications
Latest Publications
- Open Access
- 1 July 2026
- Published by BMJ in BMJ Public Health
- Vol. 4 (3) , e004782
Association between air pollution, multimorbidity and polypharmacy: a systematic review and meta-analysis
Objectives: To comprehensively examine the existing literature investigating the association between air pollution exposure and multimorbidity and/or polypharmacy. Design: Systematic review and meta-analysis. Data sources: PubMed, Web of Science, EMBASE and the Cochrane Library. Eligibility criteria: Observational studies assessed the association between air pollution and the risk of multimorbidity and/or polypharmacy among the general population were searched. Only full-text original human studies written in English up to 1 April 2026 were included. Data extraction and synthesis: Data was extracted using a standardised data extraction template and analysed using Stata SE V.19. Estimates were pooled using a random effects model, with the I 2 statistic used to estimate heterogeneity of results (PROSPERO registration: CRD42024613048). Results: In total, 22 studies met the inclusion criteria in our systematic review and 21 of 22 were included for meta-analysis. After excluding incompatible effect estimates (increment other than per 5 µg/m 3 , 10 µg/m 3 or IQR increase) and studies using overlapping datasets, four, three, two and four were included in the main meta-analysis, respectively, with a pooled adjusted risk ratio (aRR) of 1.15 (95% CI 1.08 to 1.23; I 2 =93.0%) per 5 µg/m³ particulate matter (PM) 2.5 increase, a pooled aRR of 1.27 (95% CI 1.11 to 1.47; I 2 =99.5%) per 5 µg/m³ PM 10 increase, a pooled aRR of 1.07 (95% CI 1.05 to 1.09; I 2 =0.0%) per 5 µg/m³ PM 1 increase and a pooled aRR of 1.12 (95% CI 1.00 to 1.26; I 2 =96.6%) per 5 µg/m³ nitrogen dioxide (NO 2 ) increase. There was no evidence of associations between other air pollutants (nitrogen oxides (N=3), black carbon (N=1), sulphur dioxide (N=3), ozone (N=4), carbon monoxide (N=3)) and multimorbidity. No eligible studies on polypharmacy, indoor air pollution, older adults, American and Oceanian populations were identified. Conclusions: Long-term exposure to ambient PM 2.5 and NO 2 may elevate the risk of multimorbidity. Future research should prioritise household air pollution, rural areas, older populations as a target group, continents other than Europe and Asia and polypharmacy.
- 1 July 2026
- Published by BMJ in BMJ Public Health
- Vol. 4 (3) , e004782
Open AccessAssociation between air pollution, multimorbidity and polypharmacy: a systematic review and meta-analysis
Objectives: To comprehensively examine the existing literature investigating the association between air pollution exposure and multimorbidity and/or polypharmacy. Design: Systematic review and meta-analysis. Data sources: PubMed, Web of Science, EMBASE and the Cochrane Library. Eligibility criteria: Observational studies assessed the association between air pollution and the risk of multimorbidity and/or polypharmacy among the general population were searched. Only full-text original human studies written in English up to 1 April 2026 were included. Data extraction and synthesis: Data was extracted using a standardised data extraction template and analysed using Stata SE V.19. Estimates were pooled using a random effects model, with the I 2 statistic used to estimate heterogeneity of results (PROSPERO registration: CRD42024613048). Results: In total, 22 studies met the inclusion criteria in our systematic review and 21 of 22 were included for meta-analysis. After excluding incompatible effect estimates (increment other than per 5 µg/m 3 , 10 µg/m 3 or IQR increase) and studies using overlapping datasets, four, three, two and four were included in the main meta-analysis, respectively, with a pooled adjusted risk ratio (aRR) of 1.15 (95% CI 1.08 to 1.23; I 2 =93.0%) per 5 µg/m³ particulate matter (PM) 2.5 increase, a pooled aRR of 1.27 (95% CI 1.11 to 1.47; I 2 =99.5%) per 5 µg/m³ PM 10 increase, a pooled aRR of 1.07 (95% CI 1.05 to 1.09; I 2 =0.0%) per 5 µg/m³ PM 1 increase and a pooled aRR of 1.12 (95% CI 1.00 to 1.26; I 2 =96.6%) per 5 µg/m³ nitrogen dioxide (NO 2 ) increase. There was no evidence of associations between other air pollutants (nitrogen oxides (N=3), black carbon (N=1), sulphur dioxide (N=3), ozone (N=4), carbon monoxide (N=3)) and multimorbidity. No eligible studies on polypharmacy, indoor air pollution, older adults, American and Oceanian populations were identified. Conclusions: Long-term exposure to ambient PM 2.5 and NO 2 may elevate the risk of multimorbidity. Future research should prioritise household air pollution, rural areas, older populations as a target group, continents other than Europe and Asia and polypharmacy.
- 19 January 2026
- Published by Springer Nature in Drug Safety
- Vol. 49 (6) , 677-687
Risk of Cancer Comparing Warfarin and Direct Oral Anticoagulants: Population-Based Cohort Studies in England and Hong Kong
Background Previous evidence suggests a potential protective effect of warfarin against cancer, compared to non-users. However, it may be prone to immortal time bias and residual confounding. Objective We aimed to examine the association between cancer and warfarin, compared with active comparator (direct oral anticoagulants). Methods We conducted studies using population-based databases from England and Hong Kong to investigate the association between warfarin and hazard of cancer using a new-user active-comparator cohort design. People with atrial fibrillation aged ≥ 18 years who had first received anticoagulant treatment during 01/01/2011–31/12/2019 were involved. Results No evidence supported the association between warfarin and hazard of overall cancer, compared with direct oral anticoagulants in both settings (England: hazard ratio [HR] = 1.03, 95% confidence interval [CI] 0.94–1.13; Hong Kong: HR = 0.89, 95% CI 0.79–1.01). A lower hazard of female breast (HR = 0.49, 95% CI 0.30–0.79), ovarian (HR = 0.07, 95% CI 0.01–0.58), and pancreatic (HR = 0.46, 95% CI 0.22–0.96) cancers and a higher hazard of kidney cancer (HR = 3.57, 95% CI 1.64–7.76) were found in Hong Kong, comparing warfarin with direct oral anticoagulants, but these were not replicated in England. Conclusions This study does not find a protective effect of warfarin against cancer versus direct oral anticoagulants. The risks of site-specific cancers including pancreatic, kidney, and sex-specific cancers between oral anticoagulants shown in the Hong Kong setting only may require further investigation in other independent datasets.
- 19 January 2026
- Published by Springer Nature in Drug Safety
- Vol. 49 (6) , 677-687
Risk of Cancer Comparing Warfarin and Direct Oral Anticoagulants: Population-Based Cohort Studies in England and Hong Kong
Background Previous evidence suggests a potential protective effect of warfarin against cancer, compared to non-users. However, it may be prone to immortal time bias and residual confounding. Objective We aimed to examine the association between cancer and warfarin, compared with active comparator (direct oral anticoagulants). Methods We conducted studies using population-based databases from England and Hong Kong to investigate the association between warfarin and hazard of cancer using a new-user active-comparator cohort design. People with atrial fibrillation aged ≥ 18 years who had first received anticoagulant treatment during 01/01/2011–31/12/2019 were involved. Results No evidence supported the association between warfarin and hazard of overall cancer, compared with direct oral anticoagulants in both settings (England: hazard ratio [HR] = 1.03, 95% confidence interval [CI] 0.94–1.13; Hong Kong: HR = 0.89, 95% CI 0.79–1.01). A lower hazard of female breast (HR = 0.49, 95% CI 0.30–0.79), ovarian (HR = 0.07, 95% CI 0.01–0.58), and pancreatic (HR = 0.46, 95% CI 0.22–0.96) cancers and a higher hazard of kidney cancer (HR = 3.57, 95% CI 1.64–7.76) were found in Hong Kong, comparing warfarin with direct oral anticoagulants, but these were not replicated in England. Conclusions This study does not find a protective effect of warfarin against cancer versus direct oral anticoagulants. The risks of site-specific cancers including pancreatic, kidney, and sex-specific cancers between oral anticoagulants shown in the Hong Kong setting only may require further investigation in other independent datasets.
- Open Access
- 23 December 2024
- Published by Springer Nature in BMC Medicine
- Vol. 22 (1) , 1-12
Risk of mortality between warfarin and direct oral anticoagulants: population-based cohort studies
Background: Direct oral anticoagulants (DOACs) have been reported to be associated with a higher risk of mortality compared with an older alternative, warfarin using primary care data in the United Kingdom (UK). However, other studies observed contradictory findings. We therefore aimed to investigate the association between mortality and warfarin, compared with DOACs. Methods: We conducted cohort studies using UK Clinical Practice Research Datalink (CPRD) Aurum and Hong Kong Clinical Data Analysis and Reporting System (CDARS) to identify the association between warfarin and hazard of mortality, compared to DOACs. Individuals with non-valvular atrial fibrillation aged ≥ 18 years who had first anticoagulant therapy (warfarin or DOAC) during 1/1/2011–31/12/2019 were included. Results: Compared with DOAC use, a lower hazard of all-cause mortality was found in warfarin users (hazard ratio (HR) = 0.81, 95% confidence interval (CI) = 0.77–0.86) in CPRD; while a higher hazard was observed in warfarin users (HR = 1.31, 95% CI = 1.24–1.39) in CDARS, versus DOAC users. In our exploratory analysis, consistent results were seen in both databases when stratified warfarin users by time in therapeutic range (TTR) using post-baseline measurements: a lower hazard of all-cause mortality in warfarin users with TTR ≥ 65% (CPRD: HR = 0.68, 95% CI = 0.65–0.72; CDARS: HR = 0.86, 95% CI = 0.77–0.96) and increased hazard in warfarin users with TTR < 65% (CPRD: HR = 1.14, 95% CI = 1.05–1.23; CDARS: HR = 1.59, 95% CI = 1.50–1.69), versus DOAC users. Conclusions: The differences in hazard of all-cause mortality associated with warfarin compared with DOAC, in part may depend on anticoagulation control in warfarin users. Notably, this study is unable to establish a causal relationship between warfarin and mortality stratified by TTR, versus DOACs, requiring future studies for further investigation.
- 23 December 2024
- Published by Springer Nature in BMC Medicine
- Vol. 22 (1) , 1-12
Open AccessRisk of mortality between warfarin and direct oral anticoagulants: population-based cohort studies
Background: Direct oral anticoagulants (DOACs) have been reported to be associated with a higher risk of mortality compared with an older alternative, warfarin using primary care data in the United Kingdom (UK). However, other studies observed contradictory findings. We therefore aimed to investigate the association between mortality and warfarin, compared with DOACs. Methods: We conducted cohort studies using UK Clinical Practice Research Datalink (CPRD) Aurum and Hong Kong Clinical Data Analysis and Reporting System (CDARS) to identify the association between warfarin and hazard of mortality, compared to DOACs. Individuals with non-valvular atrial fibrillation aged ≥ 18 years who had first anticoagulant therapy (warfarin or DOAC) during 1/1/2011–31/12/2019 were included. Results: Compared with DOAC use, a lower hazard of all-cause mortality was found in warfarin users (hazard ratio (HR) = 0.81, 95% confidence interval (CI) = 0.77–0.86) in CPRD; while a higher hazard was observed in warfarin users (HR = 1.31, 95% CI = 1.24–1.39) in CDARS, versus DOAC users. In our exploratory analysis, consistent results were seen in both databases when stratified warfarin users by time in therapeutic range (TTR) using post-baseline measurements: a lower hazard of all-cause mortality in warfarin users with TTR ≥ 65% (CPRD: HR = 0.68, 95% CI = 0.65–0.72; CDARS: HR = 0.86, 95% CI = 0.77–0.96) and increased hazard in warfarin users with TTR < 65% (CPRD: HR = 1.14, 95% CI = 1.05–1.23; CDARS: HR = 1.59, 95% CI = 1.50–1.69), versus DOAC users. Conclusions: The differences in hazard of all-cause mortality associated with warfarin compared with DOAC, in part may depend on anticoagulation control in warfarin users. Notably, this study is unable to establish a causal relationship between warfarin and mortality stratified by TTR, versus DOACs, requiring future studies for further investigation.
- Open Access
- 16 March 2024
- Published by Elsevier in Neuroscience & Biobehavioral Reviews
- Vol. 160, 105635
Association between prenatal antipsychotic exposure and the risk of attention-deficit/hyperactivity disorder and autism spectrum disorder: a systematic review and meta-analysis
- 16 March 2024
- Published by Elsevier in Neuroscience & Biobehavioral Reviews
- Vol. 160, 105635
Open AccessAssociation between prenatal antipsychotic exposure and the risk of attention-deficit/hyperactivity disorder and autism spectrum disorder: a systematic review and meta-analysis
- Open Access
- 27 March 2021
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 87 (11) , 4101-4123
Prenatal exposure to antipsychotic agents and the risk of congenital malformations in children: A systematic review and meta‐analysis
Objective: To evaluate the association between antipsychotic use in pregnancy and the risk of congenital malformations in children.Data sources: Searches of PubMed, EMBASE, PsycINFO and Cochrane Library were conducted from inception to 06 January 2020 using keywords: antipsychotics, pregnancy, pregnancy complication and congenital abnormalities.Study selection: Of 38 reports initially identified as being of potential interest, 13 studies met our inclusion criteria: English observational studies that examined the association between gestational antipsychotic use and congenital malformations in children.Data extraction: Data were extracted independently by 2 investigators including the publication year, study site, study period, data source, study design, sample size, medication exposure, exposure period and pregnancy definition, exposure as well as outcome ascertainment, selection of study and comparison group, confounding adjustment, statistical analysis, and method of linkage between mother and children. Risk estimates were pooled using a random‐effect model and the I2 statistic was used to evaluate the degree of heterogeneity.Results: Thirteen studies met our systematic review inclusion criteria. Six studies with a total of 2 515 272 pregnancy episodes were included in our meta‐analysis, which provided a pooled adjusted risk ratio of 1.23, 95% confidence interval: 0.96–1.58. The I2 result showed moderate heterogeneity between studies (I2 = 35.2%, P = .173).Conclusion: We did not find strong evidence of an association between prenatal exposure to antipsychotic medications and the risk of congenital malformations in children. We recommend further studies investigate this association, focusing on specific medication classes and dose responses, which would help clinicians decide whether to prescribe certain antipsychotics during pregnancy.
- 27 March 2021
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 87 (11) , 4101-4123
Open AccessPrenatal exposure to antipsychotic agents and the risk of congenital malformations in children: A systematic review and meta‐analysis
Objective: To evaluate the association between antipsychotic use in pregnancy and the risk of congenital malformations in children.Data sources: Searches of PubMed, EMBASE, PsycINFO and Cochrane Library were conducted from inception to 06 January 2020 using keywords: antipsychotics, pregnancy, pregnancy complication and congenital abnormalities.Study selection: Of 38 reports initially identified as being of potential interest, 13 studies met our inclusion criteria: English observational studies that examined the association between gestational antipsychotic use and congenital malformations in children.Data extraction: Data were extracted independently by 2 investigators including the publication year, study site, study period, data source, study design, sample size, medication exposure, exposure period and pregnancy definition, exposure as well as outcome ascertainment, selection of study and comparison group, confounding adjustment, statistical analysis, and method of linkage between mother and children. Risk estimates were pooled using a random‐effect model and the I2 statistic was used to evaluate the degree of heterogeneity.Results: Thirteen studies met our systematic review inclusion criteria. Six studies with a total of 2 515 272 pregnancy episodes were included in our meta‐analysis, which provided a pooled adjusted risk ratio of 1.23, 95% confidence interval: 0.96–1.58. The I2 result showed moderate heterogeneity between studies (I2 = 35.2%, P = .173).Conclusion: We did not find strong evidence of an association between prenatal exposure to antipsychotic medications and the risk of congenital malformations in children. We recommend further studies investigate this association, focusing on specific medication classes and dose responses, which would help clinicians decide whether to prescribe certain antipsychotics during pregnancy.
- 23 January 2020
- Published by Cambridge University Press (CUP) in Psychological Medicine
- Vol. 51 (6) , 1028-1037
The use of antipsychotic agents during pregnancy and the risk of gestational diabetes mellitus: a systematic review and meta-analysis
Background: Previous studies have found contradicting results with regard to the use of antipsychotics during pregnancy and the risk of gestational diabetes mellitus (GDM). We aimed to evaluate the association between antipsychotic use in pregnancy and GDM.Methods: A systematic literature search was conducted in PubMed, EMBASE, PsycINFO and Cochrane Library databases up to March 2019, for data from observational studies assessing the association between gestational antipsychotic use and GDM. Non-English studies, animal studies, case reports, conference abstracts, book chapters, reviews and summaries were excluded. The primary outcome was GDM. Estimates were pooled using a random effect model, with the I2 statistic used to estimate heterogeneity of results. Our study protocol was registered with PROSPERO number: CRD42018095014.Results: In total 10 cohort studies met the inclusion criteria in our systematic review with 6642 exposed and 1 860 290 unexposed pregnancies. Six studies were included in the meta-analysis with a pooled adjusted relative risk of 1.24 overall [95% confidence interval (CI) 1.09–1.42]. The I2 result suggested low heterogeneity between studies (I2 = 6.7%, p = 0.373).Conclusion: We found that the use of antipsychotic medications during pregnancy is associated with an increased risk of GDM in mothers. However, the evidence is still insufficient, especially for specific drug classes. We recommend more studies to investigate this association for specific drug classes, dosages and comorbidities to help clinicians to manage the risk of GDM if initiation or continuation of antipsychotic prescriptions during pregnancy is needed.
- 23 January 2020
- Published by Cambridge University Press (CUP) in Psychological Medicine
- Vol. 51 (6) , 1028-1037
The use of antipsychotic agents during pregnancy and the risk of gestational diabetes mellitus: a systematic review and meta-analysis
Background: Previous studies have found contradicting results with regard to the use of antipsychotics during pregnancy and the risk of gestational diabetes mellitus (GDM). We aimed to evaluate the association between antipsychotic use in pregnancy and GDM.Methods: A systematic literature search was conducted in PubMed, EMBASE, PsycINFO and Cochrane Library databases up to March 2019, for data from observational studies assessing the association between gestational antipsychotic use and GDM. Non-English studies, animal studies, case reports, conference abstracts, book chapters, reviews and summaries were excluded. The primary outcome was GDM. Estimates were pooled using a random effect model, with the I2 statistic used to estimate heterogeneity of results. Our study protocol was registered with PROSPERO number: CRD42018095014.Results: In total 10 cohort studies met the inclusion criteria in our systematic review with 6642 exposed and 1 860 290 unexposed pregnancies. Six studies were included in the meta-analysis with a pooled adjusted relative risk of 1.24 overall [95% confidence interval (CI) 1.09–1.42]. The I2 result suggested low heterogeneity between studies (I2 = 6.7%, p = 0.373).Conclusion: We found that the use of antipsychotic medications during pregnancy is associated with an increased risk of GDM in mothers. However, the evidence is still insufficient, especially for specific drug classes. We recommend more studies to investigate this association for specific drug classes, dosages and comorbidities to help clinicians to manage the risk of GDM if initiation or continuation of antipsychotic prescriptions during pregnancy is needed.
- 27 May 2019
- Published by Springer Nature in Pediatric Drugs
- Vol. 21 (3) , 153-167
Safety and Tolerability of Antipsychotic Medication in Individuals with Autism Spectrum Disorder: A Systematic Review and Meta-Analysis
Antipsychotic medication is a commonly prescribed drug class in individuals with autism spectrum disorder (ASD). However, the safety of these agents has not been fully assessed.
- 27 May 2019
- Published by Springer Nature in Pediatric Drugs
- Vol. 21 (3) , 153-167
Safety and Tolerability of Antipsychotic Medication in Individuals with Autism Spectrum Disorder: A Systematic Review and Meta-Analysis
Antipsychotic medication is a commonly prescribed drug class in individuals with autism spectrum disorder (ASD). However, the safety of these agents has not been fully assessed.
- Open Access
- 18 January 2019
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 14 (1) , e0210988
Effect of evidence-based therapy for secondary prevention of cardiovascular disease: Systematic review and meta-analysis
The combination pharmacotherapy of antiplatelet agents, lipid-modifiers, ACE inhibitors/ARBs and beta-blockers are recommended by international guidelines. However, data on effectiveness of the evidence-based combination pharmacotherapy (EBCP) is limited. To determine the effect of EBCP on mortality and Cardiovascular events in patients with Coronary Heart Disease (CHD) or cerebrovascular disease. Publications in EMBASE and Medline up to October 2018 were searched for cohort and case-control studies on EBCP for the secondary prevention of cardiovascular disease. The main outcomes were all-cause mortality and major cardiovascular events. Meta-analyses were performed based on random effects models. 21 studies were included. Comparing EBCP to either monotherapy or no therapy, the pooled risk ratios were 0.60 (95% confidence interval 0.55 to 0.66) for all-cause mortality, 0.70 (0.62 to 0.79) for vascular mortality, 0.73 (0.64 to 0.83) for myocardial infarction and 0.79 (0.68 to 0.91) for cerebrovascular events. Optimal EBCP (all 4 classes of drug prescribed) had a risk ratio for all-cause mortality of 0.50 (0.40 to 0.64). This benefit became more dilute as the number of different classes of drug comprising EBCP was decreased—for 3 classes of drug prescribed the risk ratio was 0.58 (0.49 to 0.69) and for 2 classes, the risk ratio was 0.67 (0.60 to 0.76). EBCP reduces the risk of all-cause mortality and cardiovascular events in patients with CHD or cerebrovascular disease. The different classes of drugs comprising EBCP work in an additive manner, with optimal EBCP conferring the greatest benefit.
- 18 January 2019
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 14 (1) , e0210988
Open AccessEffect of evidence-based therapy for secondary prevention of cardiovascular disease: Systematic review and meta-analysis
The combination pharmacotherapy of antiplatelet agents, lipid-modifiers, ACE inhibitors/ARBs and beta-blockers are recommended by international guidelines. However, data on effectiveness of the evidence-based combination pharmacotherapy (EBCP) is limited. To determine the effect of EBCP on mortality and Cardiovascular events in patients with Coronary Heart Disease (CHD) or cerebrovascular disease. Publications in EMBASE and Medline up to October 2018 were searched for cohort and case-control studies on EBCP for the secondary prevention of cardiovascular disease. The main outcomes were all-cause mortality and major cardiovascular events. Meta-analyses were performed based on random effects models. 21 studies were included. Comparing EBCP to either monotherapy or no therapy, the pooled risk ratios were 0.60 (95% confidence interval 0.55 to 0.66) for all-cause mortality, 0.70 (0.62 to 0.79) for vascular mortality, 0.73 (0.64 to 0.83) for myocardial infarction and 0.79 (0.68 to 0.91) for cerebrovascular events. Optimal EBCP (all 4 classes of drug prescribed) had a risk ratio for all-cause mortality of 0.50 (0.40 to 0.64). This benefit became more dilute as the number of different classes of drug comprising EBCP was decreased—for 3 classes of drug prescribed the risk ratio was 0.58 (0.49 to 0.69) and for 2 classes, the risk ratio was 0.67 (0.60 to 0.76). EBCP reduces the risk of all-cause mortality and cardiovascular events in patients with CHD or cerebrovascular disease. The different classes of drugs comprising EBCP work in an additive manner, with optimal EBCP conferring the greatest benefit.
- 13 November 2018
- Published by Springer Nature in Drug Safety
- Vol. 42 (4) , 499-513
Advances in Epidemiological Methods and Utilisation of Large Databases: A Methodological Review of Observational Studies on Central Nervous System Drug Use in Pregnancy and Central Nervous System Outcomes in Children
Studies have used various epidemiological approaches to study associations between central nervous system (CNS) drug use in pregnancy and CNS outcomes in children. Studies have generally focused on clinical adverse effects, whereas variations in methodologies have not received sufficient attention.
- 13 November 2018
- Published by Springer Nature in Drug Safety
- Vol. 42 (4) , 499-513
Advances in Epidemiological Methods and Utilisation of Large Databases: A Methodological Review of Observational Studies on Central Nervous System Drug Use in Pregnancy and Central Nervous System Outcomes in Children
Studies have used various epidemiological approaches to study associations between central nervous system (CNS) drug use in pregnancy and CNS outcomes in children. Studies have generally focused on clinical adverse effects, whereas variations in methodologies have not received sufficient attention.